Voxel-based morphometry of grey matter structures in Parkinson's Disease with wearing-off

Heng Zhai, Wenliang Fan, Yan Xiao, Zhipeng Zhu, Ying Ding, Chentao He, Wei Zhang, Yan Xu, Yuhu Zhang, Heng Zhai, Wenliang Fan, Yan Xiao, Zhipeng Zhu, Ying Ding, Chentao He, Wei Zhang, Yan Xu, Yuhu Zhang

Abstract

Our study aimed to investigate the grey matter (GM) changes using voxel-based morphometry (VBM) in Parkinson's disease (PD) patients with wearing-off (WO). 3D-T1-weighted imaging was performed on 48 PD patients without wearing-off (PD-nWO), 39 PD patients with wearing-off (PD-WO) and 47 age and sex-matched healthy controls (HCs). 3D structural images were analyzed by VBM procedure with Statistical Parametric Mapping (SPM12) to detect grey matter volume. Widespread areas of grey matter changes were found in patients among three groups (in bilateral frontal, temporal lobes, lingual gyrus, inferior occipital gyrus, right precuneus, right superior parietal gyrus and right cerebellum). Grey matter reductions were found in frontal lobe (right middle frontal gyrus, superior frontal gyrus and precentral gyrus), right parietal lobe (precuneus, superior parietal gyrus, postcentral gyrus), right temporal lobe (superior temporal gyrus, middle temporal gyrus), bilateral lingual gyrus and inferior occipital gyrus in PD-WO group compared with the PD-nWO group. Our results suggesting that wearing-off may be associated with grey matter atrophy in the cortical areas. These findings may aid in a better understanding of the brain degeneration process in PD with wearing-off.

Keywords: Grey matter; Parkinson’s Disease; Voxel-based morphometry; Wearing-off.

Conflict of interest statement

None.

© 2023. The Author(s).

Figures

Fig. 1
Fig. 1
Significant differences in GM volumes among the HC, PD-nWO and PD-WO groups. Correction for multiple comparisons (FWE, P < 0.05) was used to threshold the analysis. The color bar represents the F score. Yellow presents a high F score. Abbreviations: HC, healthy control; PD, Parkinson’s disease; WO, wearing-off; GM, grey matter; L, left, R, right
Fig. 2
Fig. 2
Significant differences in GM volumes between the HC and PD-nWO groups. Correction for multiple comparisons (FWE, P < 0.05) was used to threshold the analysis. The color bar represents the F score. Yellow presents a high F score. Abbreviations: HC, healthy control; PD, Parkinson’s disease; WO, wearing-off; GM, grey matter; L, left, R, right
Fig. 3
Fig. 3
Significant differences in GM volumes between the HC and PD-WO groups. Correction for multiple comparisons (FWE, P < 0.05) was used to threshold the analysis. The color bar represents the F score. Yellow presents a high F score. Abbreviations: HC, healthy control; PD, Parkinson’s disease; WO, wearing-off; GM, grey matter; L, left, R, right
Fig. 4
Fig. 4
Significant reductions in GM volumes between the PD-nWO and PD-WO groups. Correction for multiple comparisons (FWE, P < 0.05) was used to threshold the analysis. The color bar represents the F score. Yellow presents a high F score. Abbreviations: HC, healthy control; PD, Parkinson’s disease; WO, wearing-off; GM, grey matter; L, left, R, right
Fig. 5
Fig. 5
Correlation between the GM volumes of the right middle temporal gyrus (MTG.R) showing difference and HAMA scores in PD patients without wearing-off. The GM volumes of MTG.R was positively correlated with HAMA scores (r = 0.359, P = 0.015). The color bar represents the F score. Yellow presents a high F score. Abbreviations: HC, healthy control; PD, Parkinson’s disease; WO, wearing-off; GM, grey matter; HAMA, Hamilton Anxiety Scale; L, left, R, right

References

    1. Aiello EN, Pasotti F, Appollonio I, Bolognini N. Trajectories of MMSE and MoCA scores across the healthy adult lifespan in the Italian population. Aging Clinical and Experimental Research. 2022;34:2417–2420. doi: 10.1007/s40520-022-02174-0.
    1. Ashburner J. A fast diffeomorphic image registration algorithm. NeuroImage. 2007;38:95–113. doi: 10.1016/j.neuroimage.2007.07.007.
    1. Ashburner J, Friston KJ. Unified segmentation. NEUROIMAGE. 2005;26:839–851. doi: 10.1016/j.neuroimage.2005.02.018.
    1. Ballarini T, Mueller K, Albrecht F, Ruzicka F, Bezdicek O, Ruzicka E, Roth J, Vymazal J, Jech R, Schroeter ML. Regional gray matter changes and age predict individual treatment response in Parkinson's disease. Neuroimage-Clin. 2019;21:101636. doi: 10.1016/j.nicl.2018.101636.
    1. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del TK. Stages in the development of Parkinson's disease-related pathology. Cell and Tissue Research. 2004;318:121–134. doi: 10.1007/s00441-004-0956-9.
    1. Cacabelos R. Parkinson's Disease: From pathogenesis to pharmacogenomics. International Journal of Molecular Sciences. 2017;I:18.
    1. Cerasa A, Messina D, Pugliese P, Morelli M, Lanza P, Salsone M, Novellino F, Nicoletti G, Arabia G, Quattrone A. Increased prefrontal volume in PD with levodopa-induced dyskinesias: A voxel-based morphometry study. Movement Disorders. 2011;26:807–812. doi: 10.1002/mds.23660.
    1. Cerasa A, Pugliese P, Messina D, Morelli M, Gioia MC, Salsone M, Novellino F, Nicoletti G, Arabia G, Quattrone A. Prefrontal alterations in Parkinson's disease with levodopa-induced dyskinesia during fMRI motor task. Movement Disorders. 2012;27:364–371. doi: 10.1002/mds.24017.
    1. Cerasa A, Morelli M, Augimeri A, Salsone M, Novellino F, Gioia MC, Arabia G, Quattrone A. Prefrontal thickening in PD with levodopa-induced dyskinesias: New evidence from cortical thickness measurement. Parkinsonism & Related Disorders. 2013;19:123–125. doi: 10.1016/j.parkreldis.2012.06.003.
    1. Chan A, Cheung YF, Yeung MA, Yeung J, Chung TH, Tsang KL, Chan J, Lau C, Kwan P, Kuo SH, Mok V. A validation study of the Chinese wearing off questionnaire 9-symptom for Parkinson's disease. Clinical Neurology and Neurosurgery. 2011;113:538–540. doi: 10.1016/j.clineuro.2011.03.007.
    1. Chen H, Fang J, Li F, Gao L, Feng T. Risk factors and safe dosage of levodopa for wearing-off phenomenon in Chinese patients with Parkinson's disease. Neurological Sciences. 2015;36:1217–1223. doi: 10.1007/s10072-015-2078-4.
    1. Chen YS, Chen HL, Lu CH, Chen MH, Chou KH, Tsai NW, Yu CC, Chiang PL, Lin WC. Reduced lateral occipital gray matter volume is associated with physical frailty and cognitive impairment in Parkinson's disease. European Radiology. 2019;29:2659–2668. doi: 10.1007/s00330-018-5855-7.
    1. Cheng KL, Lin LH, Chen PC, Chiang PL, Chen YS, Chen HL, Chen MH, Chou KH, Li SH, Lu CH, Lin WC. Reduced gray matter volume and risk of falls in Parkinson's disease with dementia patients: A voxel-based morphometry study. International Journal of Environmental Research and Public Health. 2020;17(15):5374. doi: 10.3390/ijerph17155374.
    1. Chung SJ, Lee Y, Oh JS, Kim JS, Lee PH, Sohn YH. Putaminal dopamine depletion in de novo Parkinson's disease predicts future development of wearing-off. Parkinsonism & Related Disorders. 2018;53:96–100. doi: 10.1016/j.parkreldis.2018.05.008.
    1. Dirnberger G, Jahanshahi M. Executive dysfunction in Parkinson's disease: A review. Journal of Neuropsychology. 2013;7:193–224. doi: 10.1111/jnp.12028.
    1. Donzuso G, Monastero R, Cicero CE, Luca A, Mostile G, Giuliano L, Baschi R, Caccamo M, Gagliardo C, Palmucci S, Zappia M, Nicoletti A. Neuroanatomical changes in early Parkinson's disease with mild cognitive impairment: A VBM study; the Parkinson's Disease Cognitive Impairment Study (PaCoS) Neurological Sciences. 2021;42:3723–3731. doi: 10.1007/s10072-020-05034-9.
    1. Freitas ME, Hess CW, Fox SH. Motor complications of dopaminergic medications in Parkinson's disease. Seminars in Neurology. 2017;37:147–157. doi: 10.1055/s-0037-1602423.
    1. Gao Y, Nie K, Huang B, Mei M, Guo M, Xie S, Huang Z, Wang L, Zhao J, Zhang Y, Wang L. Changes of brain structure in Parkinson's disease patients with mild cognitive impairment analyzed via VBM technology. Neuroscience Letters. 2017;658:121–132. doi: 10.1016/j.neulet.2017.08.028.
    1. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Movement Disorders. 2008;23:2129–2170. doi: 10.1002/mds.22340.
    1. Hamilton M. The assessment of anxiety states by rating. British Journal of Medical Psychology. 1959;32:50–55. doi: 10.1111/j.2044-8341.1959.tb00467.x.
    1. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry. 1960;23:56–62. doi: 10.1136/jnnp.23.1.56.
    1. Hershey T, Black KJ, Carl JL, McGee-Minnich L, Snyder AZ, Perlmutter JS. Long term treatment and disease severity change brain responses to levodopa in Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry. 2003;74:844–851. doi: 10.1136/jnnp.74.7.844.
    1. Jia X, Liang P, Li Y, Shi L, Wang D, Li K. Longitudinal study of gray matter changes in Parkinson disease. American Journal of Neuroradiology. 2015;36:2219–2226. doi: 10.3174/ajnr.A4447.
    1. Jia X, Wang Z, Huang F, Su C, Du W, Jiang H, Wang H, Wang J, Wang F, Su W, Xiao H, Wang Y, Zhang B. A comparison of the Mini-Mental State Examination (MMSE) with the Montreal Cognitive Assessment (MoCA) for mild cognitive impairment screening in Chinese middle-aged and older population: A cross-sectional study. BMC Psychiatry. 2021;21:485. doi: 10.1186/s12888-021-03495-6.
    1. Jubault T, Gagnon JF, Karama S, Ptito A, Lafontaine AL, Evans AC, Monchi O. Patterns of cortical thickness and surface area in early Parkinson's disease. NeuroImage. 2011;55:462–467. doi: 10.1016/j.neuroimage.2010.12.043.
    1. Julayanont P, Tangwongchai S, Hemrungrojn S, Tunvirachaisakul C, Phanthumchinda K, Hongsawat J, Suwichanarakul P, Thanasirorat S, Nasreddine ZS. The Montreal cognitive assessment-basic: A screening tool for mild cognitive impairment in illiterate and low-educated elderly adults. Journal of the American Geriatrics Society. 2015;63:2550–2554. doi: 10.1111/jgs.13820.
    1. Katzman R, Zhang MY, Ouang-Ya-Qu, Wang ZY, Liu WT, Yu E, Wong SC, Salmon DP, Grant I. A Chinese version of the mini-mental state examination; impact of illiteracy in a Shanghai dementia survey. Journal of Clinical Epidemiology. 1988;41(971):978.
    1. Larner AJ. Screening utility of the Montreal Cognitive Assessment (MoCA): In place of–or as well as–the MMSE? International Psychogeriatrics. 2012;24:391–396. doi: 10.1017/S1041610211001839.
    1. Lee SH, Kim SS, Tae WS, Lee SY, Choi JW, Koh SB, Kwon DY. Regional volume analysis of the Parkinson disease brain in early disease stage: Gray matter, white matter, striatum, and thalamus. American Journal of Neuroradiology. 2011;32:682–687. doi: 10.3174/ajnr.A2372.
    1. Lewis MM, Du G, Sen S, Kawaguchi A, Truong Y, Lee S, Mailman RB, Huang X. Differential involvement of striato- and cerebello-thalamo-cortical pathways in tremor- and akinetic/rigid-predominant Parkinson's disease. Neuroscience. 2011;177:230–239. doi: 10.1016/j.neuroscience.2010.12.060.
    1. Li X, Xing Y, Schwarz ST, Auer DP. Limbic grey matter changes in early Parkinson's disease. Human Brain Mapping. 2017;38:3566–3578. doi: 10.1002/hbm.23610.
    1. Lim M, Loo J. Screening an elderly hearing impaired population for mild cognitive impairment using Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) International Journal of Geriatric Psychiatry. 2018;33:972–979. doi: 10.1002/gps.4880.
    1. Lindenbach D, Bishop C. Critical involvement of the motor cortex in the pathophysiology and treatment of Parkinson's disease. Neuroscience & Biobehavioral Reviews. 2013;37:2737–2750. doi: 10.1016/j.neubiorev.2013.09.008.
    1. Lu J, Li D, Li F, Zhou A, Wang F, Zuo X, Jia XF, Song H, Jia J. Montreal cognitive assessment in detecting cognitive impairment in Chinese elderly individuals: A population-based study. Journal of Geriatric Psychiatry and Neurology. 2011;24:184–190. doi: 10.1177/0891988711422528.
    1. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. Journal of the American Geriatrics Society. 2005;53:695–699. doi: 10.1111/j.1532-5415.2005.53221.x.
    1. Nyatega CO, Qiang L, Adamu MJ, Kawuwa HB. Gray matter, white matter and cerebrospinal fluid abnormalities in Parkinson's disease: A voxel-based morphometry study. Front Psychiatry. 2022;13:1027907. doi: 10.3389/fpsyt.2022.1027907.
    1. Pagonabarraga J, Soriano-Mas C, Llebaria G, Lopez-Sola M, Pujol J, Kulisevsky J. Neural correlates of minor hallucinations in non-demented patients with Parkinson's disease. Parkinsonism & Related Disorders. 2014;20:290–296. doi: 10.1016/j.parkreldis.2013.11.017.
    1. Pan PL, Shi HC, Zhong JG, Xiao PR, Shen Y, Wu LJ, Song YY, He GX, Li HL. Gray matter atrophy in Parkinson's disease with dementia: Evidence from meta-analysis of voxel-based morphometry studies. Neurological Sciences. 2013;34:613–619. doi: 10.1007/s10072-012-1250-3.
    1. Pistacchi M, Gioulis M, Sanson F, Marsala SZ. Wearing off: A complex phenomenon often poorly recognized in Parkinson's disease. A study with the WOQ-19 questionnaire. Neurology India. 2017;65:1271–1279. doi: 10.4103/0028-3886.217959.
    1. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G. MDS clinical diagnostic criteria for Parkinson's disease. Movement Disorders. 2015;30:1591–1601. doi: 10.1002/mds.26424.
    1. Rektorova I, Biundo R, Marecek R, Weis L, Aarsland D, Antonini A. Grey matter changes in cognitively impaired Parkinson's disease patients. PLoS One. 2014;9:e85595. doi: 10.1371/journal.pone.0085595.
    1. Salgado-Pineda P, Delaveau P, Falcon C, Blin O. Brain T1 intensity changes after levodopa administration in healthy subjects: A voxel-based morphometry study. British Journal of Clinical Pharmacology. 2006;62:546–551. doi: 10.1111/j.1365-2125.2006.02695.x.
    1. Si Q, Gan C, Zhang H, Cao X, Sun H, Wang M, Wang L, Yuan Y, Zhang K. Altered dynamic functional network connectivity in levodopa-induced dyskinesia of Parkinson's disease. CNS Neuroscience & Therapeutics. 2022;29(1):192–201. doi: 10.1111/cns.13994.
    1. Tessitore A, Amboni M, Cirillo G, Corbo D, Picillo M, Russo A, Vitale C, Santangelo G, Erro R, Cirillo M, Esposito F, Barone P, Tedeschi G. Regional gray matter atrophy in patients with Parkinson disease and freezing of gait. American Journal of Neuroradiology. 2012;33:1804–1809. doi: 10.3174/ajnr.A3066.
    1. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Movement Disorders. 2010;25:2649–2653. doi: 10.1002/mds.23429.
    1. Wang W, Liu X, Yang Z, Shen H, Liu L, Yu Y, Zhang T. Levodopa improves cognitive function and the deficits of structural synaptic plasticity in hippocampus induced by Global cerebral ischemia/reperfusion injury in rats. Frontiers in Neuroscience. 2020;14:586321. doi: 10.3389/fnins.2020.586321.
    1. Warren OC, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, Nissinen H, Leinonen M, Stocchi F. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Movement Disorders. 2013;28:1064–1071. doi: 10.1002/mds.25364.
    1. Wu Y, Zhang Y, Yuan X, Guo J, Gao X. Influence of education level on MMSE and MoCA scores of elderly inpatients. Applied Neuropsychology: Adult. 2023;30:414–418. doi: 10.1080/23279095.2021.1952588.
    1. xjView. (2021). A Viewing Program for SPM.
    1. Yu H, Li ML, Meng Y, Li XJ, Wei W, Li YF, Li L, Guo W, Wang Q, Deng W, Ma X, Coid J, Li T. Inferior frontal gyrus seed-based resting-state functional connectivity and sustained attention across manic/hypomanic, euthymic and depressive phases of bipolar disorder. Journal of Affective Disorders. 2021;282:930–938. doi: 10.1016/j.jad.2020.12.199.
    1. Zeng LL, Xie L, Shen H, Luo Z, Fang P, Hou Y, Tang B, Wu T, Hu D. Differentiating patients with Parkinson's Disease from normal controls using gray matter in the cerebellum. Cerebellum. 2017;16:151–157. doi: 10.1007/s12311-016-0781-1.
    1. Zhang J, Zhang YT, Hu WD, Li L, Liu GY, Bai YP. Gray matter atrophy in patients with Parkinson's disease and those with mild cognitive impairment: A voxel-based morphometry study. International Journal of Clinical and Experimental Medicine. 2015;8:15383–15392.
    1. Zhi Y, Wang M, Yuan YS, Shen YT, Ma KW, Gan CT, Si QQ, Wang LN, Cao SW, Zhang KZ. The increased gray matter volumes of precentral gyri in Parkinson's disease patients with diphasic dyskinesia. Aging (Albany NY) 2019;11:9661–9671. doi: 10.18632/aging.102412.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi